Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Telo Genomics Yönetim

Yönetim kriter kontrolleri 4/4

Telo Genomics' CEO'su Sabine Mai, Dec2023 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 3.77% doğrudan sahiptir ve bu hisselerin değeri $ 291.63K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 4.7 yıldır.

Anahtar bilgiler

Sabine Mai

İcra Kurulu Başkanı

CA$30.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	3.8%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	4.7yrs

Son yönetim güncellemeleri

Recent updates

CEO

Sabine Mai

less than a year

Görev süresi

CA$30,000

Tazminat

Dr. Sabine Mai, Ph. D. is CEO at Telo Genomics Corp since 2023 and currently serves as its Interim CEO since 2024 and previously was its Interim CEO since December 2023. She is Chair of Clinical & Scientif...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sabine Mai	Founder	less than a year	CA$30.00k	3.77% CA$ 279.5k
Sherif Louis	President & CTO	6.1yrs	CA$231.51k	Veri yok
Christopher Ross	Chief Financial Officer	3.5yrs	CA$67.50k	Veri yok

3.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim: TDSG.F 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sabine Mai	Founder	8.1yrs	CA$30.00k	3.77% CA$ 279.5k
Kenneth Anderson	Member of Clinical & Scientific Advisory Board	7.9yrs	Veri yok	Veri yok
William Meekison	Independent Director	4.7yrs	CA$18.00k	0.040% CA$ 3.0k
Ronald McGlennen	Independent Director	2.7yrs	CA$41.06k	Veri yok
Richard Bender	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Guido Baechler	Independent Chairman of the Board	5.7yrs	CA$82.12k	Veri yok
Shaji K. Kumar	Member of Clinical Advisory Board	less than a year	Veri yok	Veri yok
David Samuel Siegel	Member of Clinical Advisory Board	less than a year	Veri yok	Veri yok
Hugh A. Rogers	Independent Director	6.1yrs	Veri yok	1.42% CA$ 105.7k
James Berenson	Member of Clinical Advisory Board	less than a year	Veri yok	Veri yok
Hans Knecht	Member of Clinical & Scientific Advisory Board	7.9yrs	Veri yok	Veri yok
Ivan Borrello	Member of Clinical Advisory Board	less than a year	Veri yok	Veri yok

4.7yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TDSG.F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).

Telo Genomics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Telo Genomics Corp., Annual General Meeting, Nov 27, 2024

Telo Genomics Corp. Announces Executive Changes

Telo Genomics Corp., Annual General Meeting, Nov 30, 2023

Telo Genomics Corp Announces Chief Executive Officer Changes

Telo Genomics Corp. Appoints Richard A. Bender to Establish and Chair its MM Clinical Advisory Board

Telo Genomics Corp., Annual General Meeting, Dec 01, 2022

Recent updates

Telo Genomics Corp., Annual General Meeting, Nov 27, 2024

Telo Genomics Corp. Evaluates Minimal Residual Disease Biomarker Assay Technologies in Multiple Myeloma Patients as Part of the TELO-MRD Clinical Validation Study

Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic Tests

Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in funding

Telo Genomics Corp. Announces Executive Changes

Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone Achieved

Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting

Telo Genomics Corp., Annual General Meeting, Nov 30, 2023

Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding

Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding

Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023

Telo Genomics Corp. announced that it expects to receive CAD 2 million in funding

Telo Genomics' Multiple Myeloma Drug Resistance Study Results Selected for Presentation At the 2023 European Hematology Congress

Telo Genomics Corp Announces Chief Executive Officer Changes

Telo Genomics Corp. Launches A Minimal Residual Disease Clinical Trial in Multiple Myeloma

Telo Genomics Corp. Appoints Richard A. Bender to Establish and Chair its MM Clinical Advisory Board

Telo Genomics Corp., Annual General Meeting, Dec 01, 2022

Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples

Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma

Telo Genomics Corp. Completes the Validation of Suite of Proprietary Automation Tools

Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test

Telo Genomics Corp. Appoints Ron McGlennen as Board of Director

Telo Genomics Corp. Advances Its Lead Product and Implements Automation to Its Workflow

Telo Genomics Corp. announced that it has received CAD 2.28775 million in funding

Telo Genomics Corp. announced that it expects to receive CAD 1.5 million in funding

Telo Genomics Appoints Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy

Telo Genomics Corp., Annual General Meeting, Mar 04, 2021

Telo Genomics Corp. Announces the Positive Results of Its Smoldering Multiple Myeloma Proof of Concept Study

Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’S Disease

Telo Genomics Corp. Announces That Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within Ash 2020 Proceedings

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş